-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, it was reported that Exscientia, the leading AI pharmaceutical company in the United Kingdom, has successfully listed on the Nasdaq in the United States.
This time, a total of 15.
93 million shares were issued at an issue price of US$22 per share and a fund-raising of US$350 million
.
In addition, Exscientia also simultaneously sold 7.
27 million ADS shares, raising US$160 million, which also means that Exscientia's total fundraising reached US$510 million
.
It is reported that Exscientia plans to spend US$50 million to US$75 million to promote the development of its proprietary technology platform, and plans to spend US$25 million to US$50 million to complete the Phase I clinical study of EXS21546
.
According to data, Exscientia, headquartered in Oxford, UK, is an artificial intelligence-driven platform for drug design, discovery and development
.
It is reported that the company has advanced two drugs designed entirely by artificial intelligence to the clinical trial stage.
Currently, its R&D pipeline contains more than 20 active projects
.
According to the prospectus, Exscientia's revenue in 2020 will be 13.
35 million U.
S.
dollars and a net loss of 30.
76 million U.
S.
dollars; Exscientia's revenue in the first half of 2021 will be 7.
69 million U.
S.
dollars and a net loss of 33.
22 million U.
S.
dollars
.
Industry analysts believe that from the perspective of financial data, Exscientia is not bad for money.
At this time, the company's choice of IPO may see from the side the hotness of the AI pharmaceutical track
.
It is understood that the traditional new drug R&D model has the characteristics of low success rate, high cost, and long R&D cycle, and the "AI+Pharmaceutical" model is expected to break this dilemma
.
In recent years, with the hot research and development of new drugs and the rising cost of research and development, the field of AI pharmaceuticals has ushered in huge opportunities and the market scale has continued to expand
.
According to a report by Markets and Markets, the global artificial intelligence pharmaceutical market has huge potential.
It is expected that the global artificial intelligence pharmaceutical market will grow at a compound annual growth rate of 40.
8% from 2019 to 2024. .
In the face of the vast blue ocean of the market, the number of companies laying out the artificial intelligence pharmaceutical track is increasing.
At the same time, AI pharmaceutical companies are also accelerating the financing progress, development stage, and the pace of listing
.
Public information, in addition to Exscientia, Nasdaq AI pharmaceutical sector has been successively usher Schrodinger, Relay, Recursion, AbCelera and so on
.
In addition to overseas, the domestic capital market is also paying attention to AI pharmaceuticals
.
According to incomplete statistics, as of May 2021, there have been 11 investment and financing events in the domestic AI pharmaceutical industry.
Participants include Star Antigen (A round of 30 million US dollars), Zhihua Technology (A round of over 30 million yuan), Infineon Intelligent (Per-A round) and Kehui Intelligent (Per-A round of 150 million yuan), etc.
, have accumulated nearly 20 AI pharmaceutical companies that have received financing
.
Since the second half of this year, domestic financing in the AI pharmaceutical field has also been in full swing
.
For example, on August 16, Conmadison (Beijing) announced the completion of a Pre-A round of tens of millions of yuan in financing
.
The financing was led by BAI Capital, and the angel round led the investor Fang Fengrui Capital to further support.
The funds raised in this round are mainly used for the development of innovative small molecule drug platforms based on the three-dimensional structure of proteins and the research and development of computing-driven new drugs; 8 In November, Jingtai Technology announced the completion of a new round of Series D financing of 400 million US dollars, with a post-investment valuation of more than 13 billion yuan
.
This round of financing was led by Aobo Capital and others, and China Biopharmaceutical Group and Hopu Capital joined as new investors
.
Early shareholders such as Sequoia Capital and Wuyuan Capital continued to make additional investments; in early August, Shenzhen Technology announced that it had completed a series of tens of millions of dollars in A round of financing led by Hillhouse Ventures and co-invested by Matrix Partners China and Baitu Shengke
.
It is worth noting that this is the third round of financing completed by SZSE in a year
.
This time, a total of 15.
93 million shares were issued at an issue price of US$22 per share and a fund-raising of US$350 million
.
In addition, Exscientia also simultaneously sold 7.
27 million ADS shares, raising US$160 million, which also means that Exscientia's total fundraising reached US$510 million
.
It is reported that Exscientia plans to spend US$50 million to US$75 million to promote the development of its proprietary technology platform, and plans to spend US$25 million to US$50 million to complete the Phase I clinical study of EXS21546
.
According to data, Exscientia, headquartered in Oxford, UK, is an artificial intelligence-driven platform for drug design, discovery and development
.
It is reported that the company has advanced two drugs designed entirely by artificial intelligence to the clinical trial stage.
Currently, its R&D pipeline contains more than 20 active projects
.
According to the prospectus, Exscientia's revenue in 2020 will be 13.
35 million U.
S.
dollars and a net loss of 30.
76 million U.
S.
dollars; Exscientia's revenue in the first half of 2021 will be 7.
69 million U.
S.
dollars and a net loss of 33.
22 million U.
S.
dollars
.
Industry analysts believe that from the perspective of financial data, Exscientia is not bad for money.
At this time, the company's choice of IPO may see from the side the hotness of the AI pharmaceutical track
.
It is understood that the traditional new drug R&D model has the characteristics of low success rate, high cost, and long R&D cycle, and the "AI+Pharmaceutical" model is expected to break this dilemma
.
In recent years, with the hot research and development of new drugs and the rising cost of research and development, the field of AI pharmaceuticals has ushered in huge opportunities and the market scale has continued to expand
.
According to a report by Markets and Markets, the global artificial intelligence pharmaceutical market has huge potential.
It is expected that the global artificial intelligence pharmaceutical market will grow at a compound annual growth rate of 40.
8% from 2019 to 2024. .
In the face of the vast blue ocean of the market, the number of companies laying out the artificial intelligence pharmaceutical track is increasing.
At the same time, AI pharmaceutical companies are also accelerating the financing progress, development stage, and the pace of listing
.
Public information, in addition to Exscientia, Nasdaq AI pharmaceutical sector has been successively usher Schrodinger, Relay, Recursion, AbCelera and so on
.
In addition to overseas, the domestic capital market is also paying attention to AI pharmaceuticals
.
According to incomplete statistics, as of May 2021, there have been 11 investment and financing events in the domestic AI pharmaceutical industry.
Participants include Star Antigen (A round of 30 million US dollars), Zhihua Technology (A round of over 30 million yuan), Infineon Intelligent (Per-A round) and Kehui Intelligent (Per-A round of 150 million yuan), etc.
, have accumulated nearly 20 AI pharmaceutical companies that have received financing
.
Since the second half of this year, domestic financing in the AI pharmaceutical field has also been in full swing
.
For example, on August 16, Conmadison (Beijing) announced the completion of a Pre-A round of tens of millions of yuan in financing
.
The financing was led by BAI Capital, and the angel round led the investor Fang Fengrui Capital to further support.
The funds raised in this round are mainly used for the development of innovative small molecule drug platforms based on the three-dimensional structure of proteins and the research and development of computing-driven new drugs; 8 In November, Jingtai Technology announced the completion of a new round of Series D financing of 400 million US dollars, with a post-investment valuation of more than 13 billion yuan
.
This round of financing was led by Aobo Capital and others, and China Biopharmaceutical Group and Hopu Capital joined as new investors
.
Early shareholders such as Sequoia Capital and Wuyuan Capital continued to make additional investments; in early August, Shenzhen Technology announced that it had completed a series of tens of millions of dollars in A round of financing led by Hillhouse Ventures and co-invested by Matrix Partners China and Baitu Shengke
.
It is worth noting that this is the third round of financing completed by SZSE in a year
.
